PTC Therapeutics | PTCT - Cost Of Sales


PTC Therapeutics reported $39.61M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 28.32M 3.52M Jun/2026
Alnylam Pharmaceuticals USD 298.45M 87.33M Jun/2026
Amgen USD 1.87B 271M Jun/2026
BioCryst Pharmaceuticals USD 3.84M 5.68M Jun/2026
Biogen USD 945.1M 147.6M Jun/2026
BioMarin Pharmaceutical USD 276.29M 76.8M Jun/2026
Cytokinetics USD 5.59M 5.43M Jun/2026
Daiichi Sankyo JPY 124.29B 6.02B Jun/2026
Gilead Sciences USD 1000M 445M Jun/2026
Incyte USD 104.96M 457K Jun/2026
Ionis Pharmaceuticals USD 2.74M 261K Jun/2026
Ironwood Pharmaceuticals USD 29.83M 560K Sep/2024
Karyopharm Therapeutics USD 1.34M 139K Mar/2026
Novartis USD 3.71B 251M Jun/2026
Pfizer USD 4.09B 498M Jun/2026
PTC Therapeutics USD 39.61M 23.31M Mar/2026
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Roche Holding CHF 7.85B 630M Jun/2026
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sarepta Therapeutics USD 150.1M 40.64M Jun/2026
TG Therapeutics USD 41.19M 7.68M Jun/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 489.2M 96.4M Jun/2026
Xencor USD 61.66M 50.95M Jun/2025